1 week Ago By Defense World Staff
Medexus Pharmaceuticals Inc. ( TSE:MDP – Free Report ) – Equities research analysts at Bloom Burton reduced their Q4 2025 earnings estimates for Medexus Pharmaceuticals in a research note issued to investors on Thursday, January 23rd. Bloom Burton analyst D.
Martin now expects that the company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.01.
The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Several other research firms have also recently commented on MDP.
Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Stifel Nicolaus upped their target price on Medexus Pharmaceuticals from C$4.
15 to C$4.50 in a report on Tuesday, January 14th. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.
00 price target for the company in a research note on Wednesday, January 8th. Finally, Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a buy rating and five have given a strong buy rating to the stock.
According to data from MarketBeat.com, Medexus Pharmaceuticals has a consensus rating of “Strong Buy” and an average price target of C$5.58.
Medexus Pharmaceuticals Trading Up 10.1 % Shares of MDP opened at C$4.92 on Friday.
The stock’s 50 day moving average is C$3.25 and its two-hundred day moving average is C$2.72.
Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56.
The firm has a market capitalization of C$120.69 million, a PE ratio of 98.40 and a beta of 1.
96. Medexus Pharmaceuticals Company Profile ( Get Free Report ) Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. Further Reading Five stocks we like better than Medexus Pharmaceuticals What is the Australian Securities Exchange (ASX) Bloom Energy: Powering the Future With Decentralized Energy Comparing and Trading High PE Ratio Stocks Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul How to Calculate Stock Profit Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
